What’s newsworthy in the Trenton, N.J., and surrounding areas.
– Leading high-growth retailer specializing in hard-surface flooring offers homeowners and professionals the industry’s broadest in-stock selection of tile, natural wood, natural stone and more celebrates two new warehouse locations in East Brunswick and Parsippany, New Jersey – ATLANTA — (BUSINESS
Here’s a selection of dishes for when the snow has fallen and you’re housebound and hungry. Soups are great. Try warmer meals. — NYT: Top Stories
A winter storm expected to bring at least a foot of snow to the region has created hazardous conditions and caused flight cancellations. — NYT: Top Stories
TRENTON, N.J. — Looking forward to the next phase of the COVID-19 pandemic response, Mercer County has opened a COVID-19 vaccination facility at CURE Arena in Trenton this week. The vaccination clinic will be a partnership of the CURE Arena with Capital
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced
U.S. Food and Drug Administration assigned a target action date of May 25, 2021 PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License
—New 103,720 ft2 Facility to Serve as Headquarters and House 150 Employees in Cranbury, NJ— —State of the Art R&D Facility to Support Manufacturing Including AAV Drug Product— —cGMP Production to be Initiated in 2021 for Planned Phase 2 Study of First
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies remains under review